Patents by Inventor Régen Drouin

Régen Drouin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6410333
    Abstract: The present invention relates to the assessment of ultraviolet radiation UV effects on sunscreen-treated and non-treated human skin using a more sensitive technique.
    Type: Grant
    Filed: December 13, 1999
    Date of Patent: June 25, 2002
    Assignee: Université Laval
    Inventors: Mahmoud Rouabhia, Régen Drouin, Marc Rhainds, Joël Claveau
  • Patent number: 6210889
    Abstract: An enriched fetal cell sample is prepared from maternal blood by first separating a maternal blood sample on a three layer density gradient, and collection of the layer containing the lymphocytes and a layer immediately beneath the lymphocytes which presumably contains the nucleated fetal red blood cells and low density maternal red blood cells. The top layer in the gradient would contain the plasma and lighter components and the bottom layer would contain high density maternal red blood cells. The collected cells are then placed in a hypotonic solution and centrifuged to separate a fetal cell pellet, which contains enriched levels of fetal cells of varying types. The recovered pellet is fixed twice with Carnoy fixative and the fixed cells are then spread on a slide for FISH analysis.
    Type: Grant
    Filed: January 27, 1999
    Date of Patent: April 3, 2001
    Assignee: The Universite Laval
    Inventors: Regen Drouin, Jean-Claude Forest, Jacques Masse
  • Patent number: 6197935
    Abstract: The use of collagen as a biomedical implant raises safety issues towards viruses and prions. The physicochemical changes and the in vitro and in vivo biocompatibility of collagen treated with heat, and by formic acid (FA), trifluoroacetic acid (TFA), tetrafluoroethanol (TFE) and hexafluoroiso-propanol (HFIP) were investigated. FA and TFA resulted in extensive depurination of nucleic acids while HFIP and TFE did so to a lesser degree. The molecules of FA, and most importantly of TFA, remained within collagen. Although these two acids induced modification in the secondary structure of collagen, resistance to collagenase was not affected and, in vitro, cell growth was not impaired. Severe dehydrothermal treatment, for example 110° C. for 1-3 days under high vacuum, also succeeded in removing completely nucleic acids. Since this treatment also leads to slight cross-linking, it could be advantageously used to eliminate prion and to stabilize gelatin products.
    Type: Grant
    Filed: September 29, 1998
    Date of Patent: March 6, 2001
    Assignee: DiagnoCure, Inc.
    Inventors: Charles Doillon, Régen Drouin, Gaétan LaRoche